This post was originally published on here A research team led by Professor Jiwoong Yang of the Department of Energy Science and Engineering at DGIST has developed the world’s first foundational technology for an ultrahigh-resolution stretchable …
Driving out in the early morning hours to fix damaged signs was a frequent routine for Greene-Placentia, who intended to avoid daytime traffic and extreme summer heat
Bernadette Greene-Placentia says she is sharing her story in order to fight for victims of sexual assault
This post was originally published on here In order to cultivate wisdom for the age of AI, we ought to slow down to ask what is gained, what is lost, and what is changing …
By JOCELYN NOVECK “He has to go and live on the edge,” explains Lina Móey about her husband, the Icelandic mountaineer John Snorri Sigurjonsson, in “The Last First: Winter K2.” And she means it literally: He has…
This post was originally published on here Marvell Technology (NASDAQ:MRVL) has outperformed the market over the past 20 years by 5.75% on an annualized basis producing an average annual return of 14.82%. Currently, Marvell Technology has a market capitalization
RESEARCH TRIANGLE PARK, N.C., October 07, 2026–IQVIA (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries, today at TechIQ 2026 introduced IQVIA Life Science ModelsTM to help predict clinical trial outcomes.
Read on for updates across the Research we Enable Postmortem Tissue (PMT) Core The Target ALS Postmortem Core has now collected brain and spinal cord tissue from over 650 cases, making it the largest and most comprehensive ALS tissue repository worldwide that is accessible with no-strings-attached to the global research community. This robust and expanding […]
By Evan Perez, Hannah Rabinowitz, Kara Scannell, Jennifer Hansler, CNN (CNN) — Prosecutors in New York are expected to bring new charges against
The Target ALS Global Natural History Study (GNHS) is entering a new phase of discovery. As the only international, longitudinal study generating deeply characterized clinical, genomic, and biofluid data to accelerate ALS biomarker discovery and therapeutic development, the GNHS is now beginning to deliver large scale datasets and resources needed to support new insights into […]